

James Brett Case

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1115987/james-brett-case-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

5,911
citations

28
h-index

69
g-index

69
ext. papers

9,420
ext. citations

25.1
avg. IF

5.96
L-index

#	Paper	IF	Citations
64	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.. <i>Nature</i> , 2022 ,	50.4	89
63	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.. <i>MBio</i> , 2022 , e03238218	7.8	1
62	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.. <i>MBio</i> , 2022 , e0337721	7.8	2
61	Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice. 2022 ,		6
60	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022 , 14,	17.5	9
59	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.. <i>Cell</i> , 2022 ,	56.2	3
58	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting.. <i>Cell Reports</i> , 2022 , 110561	10.6	1
57	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , 2022 , 14, eabn1252	17.5	3
56	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.. <i>Journal of Clinical Investigation</i> , 2022 ,	15.9	1
55	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies. <i>Cell Reports</i> , 2022 , 110905	10.6	0
54	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.. <i>Cell Reports</i> , 2021 , 37, 110143	10.6	16
53	The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. 2021 ,		17
52	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. <i>Cell Host and Microbe</i> , 2021 ,	23.4	14
51	SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice. <i>Journal of Virology</i> , 2021 , JVI0151121	6.6	15
50	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021 , 37, 109881	10.6	6
49	JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 2021 ,		8
48	A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants 2021 ,		9

47	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice 2021 ,		1
46	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021 , 27, 717-726	50.5	497
45	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains 2021 ,		2
44	A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope 2021 ,		6
43	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021 , 184, 2183-2200.e22	56.2	145
42	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021 , 184, 1804-1820.e16	56.2	149
41	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. <i>Cell Reports Medicine</i> , 2021 , 2, 100230	18	40
40	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity 2021 ,		13
39	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021 , 557, 70-85	3.6	18
38	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021 , 596, 109-113	51.3	203
37	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021 , 596, 103-108	50.4	91
36	A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. <i>Cell Reports</i> , 2021 , 36, 109400	10.6	35
35	Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail 2021 ,		28
34	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques 2021 ,		5
33	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies 2021 ,		39
32	Multivalent designed proteins protect against SARS-CoV-2 variants of concern 2021 ,		4
31	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021 , 29, 1151-1161.e5	23.4	11
30	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021 , 54, 2399-2416.e6	32.3	30

29	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021 , 54, 2159-2166.e6	32.3	27
28	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021 , 6, 1233-1244	26.6	72
27	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. <i>Journal of Molecular Biology</i> , 2021 , 433, 167177	6.5	10
26	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020 , 583, 290-294	30.4	1028
25	Growth, detection, quantification, and inactivation of SARS-CoV-2. <i>Virology</i> , 2020 , 548, 39-48	3.6	99
24	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. <i>Cell</i> , 2020 , 182, 744-753.e4	56.2	337
23	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020 , 28, 475-485.e5	23.4	252
22	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , 2020 , 205, 915-922	5.3	126
21	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020 , 26, 1422-1427	50.5	283
20	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020 , 3606354	1	12
19	Structural and functional analysis of a potent sarbecovirus neutralizing antibody 2020 ,		42
18	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 2020 ,		10
17	Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis 2020 ,		9
16	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations 2020 ,		8
15	A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters 2020 ,		18
14	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection 2020 ,		29
13	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020 , 183, 169-184.e13	56.2	221
12	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020 , 21, 1506-1516	19.1	272

11	LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. <i>Nature</i> , 2020 , 588, 308-314	50.4	22
10	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 32105-32113	11.5	96
9	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , 2020 , 28, 465-474.e4	23.4	106
8	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 20803-20813	11.5	87
7	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020 , 584, 443-449	50.4	609
6	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020 , 370, 950-957	33.3	314
5	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. <i>Clinical Chemistry</i> , 2020 , 66, 1538-1547	5.5	70
4	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , 2020 , 370, 426-431	33.3	219
3	A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection		5
2	SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans		4
1	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains		3